Background: Several classes of biologic agents are used for the management of moderate to severe psoriasis or psoriatic arthritis. However, there is uncertainty on which, if any, individual class of biologics is superior in terms of efficacy and safety in comparison to the other classes or placebo. We thus exploited the corresponding evidence network with suitable statistical methods (mixed treatment comparison and network meta-analysis) to formally address this issue.
INTRODUCTION
The management of psoriasis has dramatically improved in terms of efficacy and effectiveness since the introduction of biologic therapy [1] . Biologic agents include those which block tumor necrosis factor-(TNF-) [anti-TNF-agents), as well as those inhibiting T lymphocytes (anti-T-cell agents), anti-interleukin-12/23 (IL-12/23) agents, and anti-interleukin-17 (IL-17) agents [2] . Given the availability of several different individual agents for each of the above classes, the scholarly literature now includes several trials *Address correspondence to this author at the Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Corso della Repubblica 79, 04100 Latina, Italy; Tel: +39 07731757245; Fax: +39 07731757254; E-mail: giuseppe.biondizoccai@uniroma1.it comparing different agents against placebo, against standard care, or against active controls [3] [4] .
While clinicians wishing to decide which treatment is better eventually focus on the comparative efficacy and safety of a specific molecule, they often tend to preliminarily assume that class effects are present [5] . Thus they routinely approach a management decision by also looking at the risk-benefit profile of therapeutic classes. Several research groups [6] [7] [8] [9] [10] have independently tried to appraise and compare individual biologics for the management of psoriasis. Conversely, there is no work hitherto dedicated to class effects of biologic agents for psoriasis.
Given the complex evidence base on this topic, a naïve approach wishing to summarize such data with a straightforward systematic review and pairwise metaanalysis would provide fewer quantitative estimates, of spurious precision and limited external validity [11] . Yet, tackling this apparent conundrum with the recently refined statistical methods enabling network metaanalysis and mixed treatment comparison holds the promise of a more robust and valid set of quantitative results [12] [13] [14] . Indeed, a systematic review uses explicit and established methods for evidence search, selection and appraisal. A pairwise meta-analysis combines statistically data from similar head-to-head randomized trials (e.g. 3 studies comparing treatment A and treatment B). Conversely, a network meta-analysis and mixed treatment comparison uses the whole set of clinical evidence on a specific condition and focusing on similar treatments in order to identify the treatment with the most favorable risk-benefit balance (e.g. 3 studies comparing treatment A and treatment B, 1 study comparing treatment A and treatment C, and 2 studies comparing treatment B and treatment C [11] .
The key strengths of these novel statistical methods is that they can distinguish also class effect from agentspecific effects, an aspect of great importance whenever different agents within the same pharmacologic class are available. Accordingly, assuming a prevalent class effect in this therapeutic realm, and exploiting a recent systematic review and agent-level network metaanalysis conducted by our research group on this very topic [15] , we aimed to review the current evidence based and explicitly focus on the appraisal of the efficacy and safety of different classes of biologics in patients with moderate to severe plaque psoriasis or psoriatic arthritis.
METHODS

Review Design
This review and the parent one from which the present stems [15] were conducted in compliance with the Quality of Reporting of Meta-analyses (QUOROM) and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [16] [17] . All reviewing activities were performed independently by two experienced reviewers, with divergences solved after consensus.
Database Search and Study Selection
Pertinent studies were searched in MEDLINE/PubMed online database according to the search strategy dedicated to randomized clinical trials previously reported by Biondi-Zoccai et al. [18] . In addition, other key online databases such as The Cochrane Library, Google Scholar, and Scopus were searched for suitable studies. The search was last updated on October 2013. No language restriction was enforced, thus enabling the inclusion of studies reported in English as well as in other languages.
Initially retrieved citations were screened at the title/abstract level and then retrieved as full texts if potentially pertinent. Full reports were included if reporting on patients with moderate to severe psoriasis or psoriatic arthritis receiving biologic agents, and included in a randomized trial. Studies were excluded if not based on random allocation, duplicates, lacking details on clinical efficacy or safety outcomes, or focusing on agents which had been discontinued before or shortly after market approval for safety issues [19] .
Data Extraction
Key baseline, procedural and outcome data were systematically retrieved, focusing specifically on efficacy and safety outcomes. For the purpose of this review, we focused on 4 separate classes of 12 individual biologic agents: anti-IL-12/23 agents (briakinumab, ustekinumab); anti-IL-17 agents (brodalumab, iIxekinumab, secukinumab); anti-T-cell agents (abatacept, alefacept); anti-TNF-agents (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab) [2, 20] .
As efficacy outcomes, we focused on the binary rates of reduction 75% in the Psoriasis Area and Severity Index (PASI75), which is a validated endpoint for the assessment of the extent of psoriasis, and improvement 20% in the American College of Rheumatology core set of outcomes (ACR20), which is a validated endpoint for the assessment of the extent of arthritis, both at the longest available follow-up. As safety outcomes, we focused on serious adverse events (SAE), and adverse events (AE), which are validated endpoints in the assessment of drug safety, both at the longest available follow-up.
Statistical Analysis
Continuous variables are described as median and categorical variables as %. Pairwise meta-analysis was performed within a frequentist framework computing DerSimonian-Laird random-effect risk ratios (RR) with 95% confidence intervals [11] . Network meta-analysis and mixed treatment comparison was performed within a Bayesian framework with a random-effect binomial likelihood hierarchical model, sampling effect estimates with Markov chain Monte Carlo (MCMC) methods with Gibbs sampling, computing RR with 95% credibility intervals, and probability of being the best treatment for each agent (Pbest, which is a quantitative estimate of the posterior likelihood that a given treatment is most likely to yield the most favorable results for the specific endpoint of interest) [11, 13] . Such credibility intervals can be interpreted at large in a similar fashion as confidence intervals for the purpose of clinical decisionmaking [21] . Analyses were based on two separate sets of computer simulations, in keeping with the MCMC method: a 50,000-run training set (with corresponding estimates being discarded) and a 150,000-run inferential set (used for inferential estimates). Convergence of the three chains stemming from different and separate initial values was appraised with the Gelman-Rubin method (which showed adequate convergence at the 50,000-run threshold. Model fit was appraised with the deviance information criterion (DIC), comparing random-effect and fixed-effect models, with choice a fixed-effect model preferred at similar DIC values for parsimony sake. Pairwise consistency (i.e. the agreement between estimates stemming from trials having the same type of comparators) was appraised with I-squared and consistency between direct and indirect estimates was appraised by comparing consistency and inconsistency models [11] . Small study effects and publication bias (i.e. the phenomenon in which small studies provide over-optimistic results, possibly due to their selective publication) were appraised with visual inspection of funnel plot (graphical plots assessing the association between effect estimates and study precision). Computations were performed with RevMan 5 (The Denmark Cochrane Center, Copenhagen, Denmark), and WinBUGS (MRC Biostatistics Unit, University of Cambridge, Cambridge, UK).
RESULTS
From an initial set of 21,475 citations, 21,286 were excluded at the title/abstract screening stage ( Figure  1) . Thereafter, 189 articles were appraised as full reports, leading to the eventual inclusion of a total of 58 trials and 18,508 patients. The main reason for exclusion of full reports was duplication of trial data, followed by observational design, and meta-analysis as study type.
The included studies compared, with variable assortments, placebo and 14 different pharmacologic agents (12 biologics) grouped in 5 main classes: anti-IL-12/23 agents (briakinumab, ustekinumab); anti-IL-17 agents (brodalumab, ixekinumab, secukinumab); anti-T-cell agents (abatacept, alefacept); anti-TNF-agents (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab); and other agents (acitretin, methotrexate) (Table 1; Figure 2) .
Pairwise meta-analyses were performed for PASI75 (Figure 3) , ACR20 (Figure 4) , SAE (Figure 5) , and AE (Figure 6 ). Whereas PASI75 rates were highest with anti-IL-12/23 agents (RR=12.11 [8.16-17 .97], p<0.001), ACR20 was best achieved by anti-TNF-agents (RR=3.53 [2.86-4.36], p<0.001) and anti-T-cell agents (RR=2.13 [1.10-4.12], p=0.02). Conversely, SAE rates were not significantly increased by any class of biologics. Finally, AE were significantly more common with anti-IL-12/23 (RR=1.06 [1.00-1.13], p=0.04) or anti-TNF-agents than with placebo (RR=1.07 [1.02-1.13], p=0.009). Overall, pairwise inconsistency was mild, and funnel plot inspection based on such data did not suggest the presence of small study effects.
Network meta-analysis, exploiting both direct and indirect class-level comparisons, showed that several classes biologic agents provided higher PASI75 rates than placebo ( 
DISCUSSION
This review, the first to comprehensive appraise and quantify the risk-benefit profile of different classes of biologic agents in the management of moderate to severe psoriasis or psoriatic arthritis has the following main implications: a) the evidence base on this topic, despite being mainly dominated by placebo-controlled .0 suggesting that the agents of choice are better than placebo or the best class, and RR<1.0 suggesting that the agents of choice are worse than placebo or the best class; IL=interleukin; TNF=tumor necrosis factor. *Rate ratios far from 1.0 indicate credibly different rates, with RR<1.0 suggesting that the agents of choice are better than placebo or the best class, and RR>1.0 suggesting that the agents of choice are worse than placebo or the best class; IL=interleukin; TNF=tumor necrosis factor. trials, is sufficiently comprehensive and consistent to enable precise estimation of efficacy and safety of the different class types of biologics; b) application of network meta-analysis methods to this topic yields quantitative estimates of the relative efficacy and safety of such classes, showing that anti-IL-17 and anti-TNFagents appear the most effective ones, and anti-T-cell agents appear the safest ones; and c) this work, building upon a prior analysis on the very same set of data but exploiting an agent-level focus [15] , provides a clear example of the potential usefulness of mixed treatment comparison methods in summarizing apparently complex sets of data and guide, despite the inherent limitation of these approaches and the many assumptions, clinical decision making.
The outlook of patients with more than mild psoriasis or suffering from psoriatic complications such as arthritis has momentously changed thanks to the introduction of biologic therapy, which is based on disease modifying pharmacologic agents capable of substantial effects on the pathophysiologic mechanisms underlying this condition, while concomitantly minimizing, as much as possible toxicity [22] . The pioneering successes of the first trials on biologics in psoriasis have lead to the progressive increase in the availability of agents from the same pharmacologic class, as well as from other classes. Accordingly, while it appears evident that biologics are now a mainstay in moderate to severe psoriasis or psoriatic arthritis, it is also true that clinicians face the dilemma of choosing first the class of agents with the most favorable risk-benefit profile, and then, within that specific class, the best agent [23] .
This line of thinking is based on the widespread assumption in clinical medicine and pharmacology that drugs have a class effect, with only minor differences between individual agents belonging to the same class [5] . This assumption has been challenged in several settings and is difficult to prove unless a comprehensive evidence base is available. Yet, the human mind, and, in particular, the clinician's mind relies often on this assumption, as do the research and development units of pharmacologic companies when aiming at developing a specific novel or "me-too" agent.
Several independent researchers have recently provided a comprehensive and synthetic appraisal of the risk-benefit profile of specific and individual biologic agents in the management of psoriasis. However, no formal appraisal of the presence of class effects is hitherto available, neither in our recent work nor in other similar ones. Yet, this clinical question appears interesting and scientifically important. If differences between individual biologic agents have nothing to do with the corresponding class, then hypothetically a class-level analysis will not be evident, and no significant differences will appear between the different classes or versus placebo. Conversely, if a class effect does exist, then hypothetically we should be able to demonstrate beyond random variability that a given class is superior or inferior to other classes or to placebo. This is indeed what we found, thus demonstrating that class effects are present and impact on risk and benefit of biologic therapy.
Specifically, our work shows that anti-IL-17 agents are the most promising ones when treating patients with moderate to severe psoriasis and aiming for the highest likelihood of achieving a PASI75 result (i.e. a reduction 75% in the Psoriasis Area and Severity Index). When the goal is instead achieving an improvement 20% in the American College of Rheumatology core set of outcomes in patients with psoriatic arthritis, TNF-agents appear the most promising. Conversely, if the risks of adverse effects of biologic therapy need to be minimized, then anti-T-cell agents appear as the safest option. Clinicians might exploit this piece of evidence when initially treating a patient to choose the class of agents with the most favorable risk-benefit profile in keeping with the specific individual disease severity as well as likelihood of adverse effects. Moreover, awareness of these class effects might help in changing from an individual biologic agent to another from the same class if there are agent-specific intolerances or contraindications. Physicians might thus move from a class to a different one depending on the response to the initial biologic therapy and changes in treatment goals. Similar findings, despite some minor differences mainly stemming from the diverse pools of included studies, have been reported by other authors, who however only focused on agent-level analyses [6] [7] [8] [9] [10] .
From a more poignant statistical perspective, this work provides a clear example of the pros and cons of exploiting by means of mixed treatment comparison methods a complex evidence network [11, [24] [25] [26] . We hereby emphasize class effects, whereas previous works mainly emphasized agent-specific effects. Both approaches may appear partial and somewhat naïve, but they both contribute in understanding and making sense of the complexity of randomized trials focusing on biologics in psoriasis. The robustness of our findings is testified by the similar results achieved at agent-and class-level analyses, by the concordance of analysis based on fixed-or random-effects methods, and by the coherent results stemming from consistent and inconsistent models [6] .
Limitations of this review are substantial, and go beyond those typical of network meta-analyses and mixed treatment comparisons [11] . A key limitation is the reliance, for efficacy appraisal, on subjectively collected and measured endpoints, and, for safety appraisal, on adverse outcomes which may be too sensitively collected, thus lacking specificity and clinical relevance [27] . In addition, the prevalent star shape of the evidence network may hinder the robustness of indirect estimates for some comparisons. In addition, follow-up was limited to few months, thus limiting our inferential strength on long-term efficacy and safety results. It must also be emphasized that this work builds upon a prior agent-level meta-analysis recently published in this Journal by our group. It however provides additional results and insights and may thus help to guide clinical decision making, highlighting the pros and cons of using a class-level rather than an agent-level approach when quantifying the risk-benefit balance of biologic agents in psoriasis. Finally, the lack of simultaneous agent-and class-level effects or metaregression adjustment for key moderators may provide spuriously precise results. Accordingly, further analyses will be necessary to corroborate our present findings when adequately powered head-to-head randomized trials have been conducted and reported.
In conclusion, biologic agents provide significant clinical benefits in patients with moderate to severe psoriasis or psoriatic arthritis. There are differences in the efficacy and safety profile for each class of agents, with anti-IL-17 and anti-TNF-agents appearing most effective, and anti-T-cell agents appearing safest. Clinicians should bear in mind these features to maximize safety and efficacy of biologic therapy in the individual patient.
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